Kit Wong, MD
Disclosures: I/we have no financial relationships to report.

Bio:

Kit Man Wong, MD              Curriculum Vitae              AUGUST 2017

CURRICULUM VITAE                                                                                                                                               AUGUST 2017

KIT MAN WONG, MD

 

  1. EDUCATION

2001-2005              HBSc (with High Distinction), Biochemistry Specialist, University of Toronto, Toronto, ON, Canada

2005-2009              MD, University of Toronto, Toronto, ON, Canada

 

  1. POSTGRADUATE TRAINING

2009-2012              General Internal Medicine Residency, University of Toronto, Toronto, ON, Canada

2012-2014              Medical Oncology Fellowship, University of Toronto, Toronto, ON, Canada

2014-2016              Developmental Therapeutics Fellowship, Division of Medical Oncology, University of Colorado, Aurora, CO

 

  1. FACULTY POSITIONS HELD

2016-              Assistant Professor of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA

2016-              Assistant Member, Division of Clinical Research, Fred Hutchison Cancer Research Center, Seattle, WA

 

  1. HOSPITAL POSITIONS HELD

2016-              Attending Physician, Seattle Cancer Care Alliance, Seattle, WA

2016-              Attending Physician, University of Washington Medical Center, Seattle, WA

 

  1. HONORS

2002              BIO150Y Outstanding Achievement Award, Departments of Botany and Zoology, University of Toronto, Toronto, ON, Canada

2002              The Chinese Canadian Association of Biomedical Professionals Scholarship, University of Toronto, Toronto, ON, Canada

2001-2004              The University of Toronto Scholarship, University of Toronto, Toronto, ON, Canada (three-time award winner)

2002-2004              Dr. James A. & Coonie P. Dickson Scholarship in Sciences and Mathematics, University College, University of Toronto, Toronto, ON, Canada (three-time award winner)

2002-2005              Dean’s List, Years I, II, III, IV, University of Toronto, Toronto, ON, Canada

2004              Life Sciences Committee Summer Research Award, University of Toronto, Toronto, ON, Canada

2005              Advanced Biochemistry Laboratory Coordinators Award, Department of Biochemistry, University of Toronto, Toronto, ON, Canada

*2005              University College Gold Medal for Best Degree (Bachelor of Science), University College, University of Toronto, Toronto, ON, Canada

2005              Samuel Godfrey Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006              Chinese-Canadian Medical Society Award in Metabolism and Nutrition, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006              CREMS Summer Research Award, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006              Clara Adela Brown, M.D. Memorial Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006              Norris & Rita Rodbard Memorial Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006-2008              Dr. C.S. Wainwright Memorial Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2006-2009              Honors Standing, Years I, II, III, IV, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2007              Heart and Stroke Foundation of Ontario Summer Studentship Award

2007              Pilari Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2007              Mary L. Cassidy Award, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2008              Albert & Rose Jong Medical Alumni Association Student Award, Medical Alumni Association, University of Toronto, Toronto, ON, Canada

2008              Geoffrey Samuel Gangbar Memorial Scholarship, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2009              Dr. Herbert Alexander Bruce Medal, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

*2009              Cody Silver Medal, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2011              Third Place Abstract Winner, 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, New York, NY, USA, November 3-4, 2011

2011              University of Toronto Physicians’ Services Incorporated (PSI) Foundation Resident Research Prize for Excellence in Research Papers, PSI Foundation

2012              Novartis Oncology Young Canadian Investigator Award

2012              American Society of Clinical Oncology (ASCO) Merit Award, ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012

2013              Second Place Abstract Winner, Canadian Association of Medical Oncologists (CAMO) Annual Scientific Meeting, Toronto, ON, Canada, April 25, 2013

2013              American Society of Clinical Oncology (ASCO) Merit Award, ASCO Annual Meeting, Chicago, IL, USA, May 31-June 4, 2013

2013              Joseph M. West Family Memorial Fellowship (Postgraduate Research Award), University of Toronto, Toronto, ON, Canada

2013              Heidi Sternbach Scholarship (Postgraduate Research Award), University of Toronto, Toronto, ON, Canada

2013              Chisholm Memorial Fellowship (Postgraduate Research Award), University of Toronto, Toronto, ON, Canada

*2013              Starr Medal (Postgraduate Research Award), University of Toronto, Toronto, ON, Canada

2013              CCSRI Travel Award, Canadian Cancer Society Research Institute

*2014              CIHR/CAMO Fellowship Award, Canadian Institutes of Health Research/Canadian Association of Medical Oncology

*2014              ASCO Young Investigator Award, Conquer Cancer Foundation of the American Society of Clinical Oncology

2016              American Society of Clinical Oncology (ASCO) Merit Award, ASCO Annual Meeting, Chicago, IL, USA, June 3-7, 2016

 

  1. BOARD CERTIFICATION

2013              Fellow of the Royal College of Physicians and Surgeons of Canada (Internal Medicine)

2013              Diplomate of the American Board of Internal Medicine

2014              Fellow of the Royal College of Physicians and Surgeons of Canada (Medical Oncology)

2014              Diplomate of the American Board of Internal Medicine in Medical Oncology

 

  1. LICENSURE

2013-2016              Independent Practice License, College of Physicians and Surgeons of Ontario, Canada

2014-2016              Physician Training License, Colorado

2016-              Physician License, Washington

 

  1. PROFESSIONAL ORGANIZATIONS

2005-2014              Ontario Medical Association

2005-2014              Canadian Medical Association

2009-2014              The Professional Association of Internes and Residents of Ontario

2012-              American Society of Clinical Oncology

2013-              Canadian Association of Medical Oncologists

 

  1. TEACHING RESPONSIBILITIES

2007              Clinical skills instructor, UT Clinical Skills Mentorship Group, University of Toronto

2010-2011              Clinical skills instructor, Arts and Science of Clinical Medicine course (medical students), Faculty of Medicine, University of Toronto

2010-2011              Seminar leader, Ethics and Professionalism seminars (medical students), Faculty of Medicine, University of Toronto

2011-2012              Committee representative, General Internal Medicine Residency Training Committee, University Health Network and Mount Sinai Hospital, University of Toronto

2012              Seminar leader (neoplasia seminar), Foundations of Medical Practice course (medical students), Faculty of Medicine, University of Toronto

2012              Resident teaching (basics of chemotherapy), Medical Oncology rotation seminar, Sunnybrook Health Sciences Centre, University of Toronto

2016              Lecturer, “GI malignancies: emphasis on colorectal cancer,” core internal medicine resident teaching, VA Puget Sound Health Care System, Seattle, WA, August 15, 2016.

 

  1. Fellows and post-doctoral fellows

2017              Courtney Bishop (pharmacy resident), observer, longitudinal clinic, February – June 2017.

 

  1. Local talks

2011              “Lemierre syndrome with severe neurological complications.” Medical Grand Rounds, Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, ON, Canada, June 8, 2011. (3rd Place Winner of the UHN/MSH Great Cases in Medicine Competition for 2010-2011)

2012              “Lymphoma and renal failure.” Department of Hematology Grand Rounds, Sunnybrook Health Sciences Centre, ON, Canada, September 17, 2012.

2012              Hepatocellular carcinoma: review of current management and new evidence.GI Site Group Rounds, Sunnybrook Health Sciences Centre, ON, Canada, November 19, 2012.

2013              Hepatocellular carcinoma: review of current management and new evidence. Department of Medical Oncology and Hematology Grand Rounds, Princess Margaret Cancer Centre, ON, Canada, February 14, 2013.

2013              Review of targeted therapies in unresectable metastatic colorectal cancer.” GI Site Group Rounds, Sunnybrook Health Sciences Centre, ON, Canada, December 2, 2013.

2017              An eMERging target in colorectal cancer: preclinical and future clinical development.” Phase 1 Program meeting, Seattle Cancer Care Alliance, Seattle, WA, January 27, 2017.

2017              “Immunobiology of hepatocellular carcinoma and radiation.” Hepatic Oncology Seminar meeting, University of Washington, Seattle, WA, June 12, 2017.

2017              “Gastroenteropancreatic neuroendocrine tumors.” GI meeting, Seattle Cancer Care Alliance, Seattle, WA, June 15, 2017.

 

  1. SPECIAL LOCAL RESPONSIBILITIES

2005-2006              Student Representative, Comprehensive Research Experience for Medical Students Advisory Committee, Faculty of Medicine, University of Toronto

2006-2007              Leader, MEDLIFE (Division of Career Exploration and Development), Medical Society, University of Toronto

2007              Director, Comprehensive Research Experience for Medical Students Research Day, Faculty of Medicine, University of Toronto

2012              Examiner, National Assessment Collaboration, Centre for the Evaluation of Health Professionals Educated Abroad (CEHPEA), Toronto, Ontario

 

  1. RESEARCH FUNDING

2014-2015              Sponsor: Conquer Cancer Foundation, American Society of Clinical Oncology

Title: Exploiting the Receptor Tyrosine Kinase MER for the Targeted Therapy of Colorectal Cancer

Total Costs: $50,000

Role: PI             

2014-2016              Sponsors: Canadian Institutes of Health Research, Canadian Association of Medical Oncology

Title: Exploiting the Receptor Tyrosine Kinase MER for the Targeted Therapy of Colorectal Cancer

Total Costs: $120,000 CDN

Role: PI             

 

  1. RESEARCH EXPERIENCE

2014-2016              Preclinical research

Validation of MER as molecular target and evaluation of the novel MER inhibitor UNC2025 in colorectal cancer models (mentor: Dr. Gail Eckhardt)

University of Colorado Anschutz Medical Campus, Denver, CO

2014-2016              Phase 1 clinical trials and GI clinical trials

                            Sub-Investigator in all trials, Developmental Therapeutics Program and GI Research Program

University of Colorado Anschutz Medical Campus, Denver, CO

2016-                            Phase 1 clinical trials and GI clinical trials

                            Principal Investigator (see below) and Sub-Investigator (in over 30 Phase 1 trials and over 30 GI research trials), Phase 1 Program and GI Research Program (mentors: Dr. Laura Chow and Dr. Gabriela Chiorean)

                            Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA

 

  1. Clinical trials as PI

2017 (Co-PI)              A phase 1/2 study exploring the safety, tolerability, effect on the tumor microenvironment, and efficacy of azacitidine in combination with pembrolizumab and epacadostat in subjects with advanced solid tumors and previously treated stage 3B or stage 4 non-small cell lung cancer and stage 4 microsatellite-stable colorectal cancer (Incyte)

2017                            A phase 1A/1B open-label, dose-escalation study of the safety and pharmacokinetics of RO7198457 as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic tumors (Genentech)

2017              Study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab for patients with advanced unresectable biliary tract cancer (BMS) (pending)

2017              A phase 2 trial of the CDK4/6 inhibitor abemaciclib in advanced and refractory well-differentiated gastroenteropancreatic neuroendocrine tumors (investigator-initiated trial, Eli Lilly) (pending)

2017               A phase 1/2a open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study of IMX110 in participants with advanced solid tumours (Immix Biopharma Australia) (pending)

 

  1. Clinical trials as Sub-I

Multiple (list can be provided upon request)

 

  1. BIBLIOGRAPHY
  1. Publications in refereed journals
    1. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Leibbrandt A, Makovic M, Schwaighofer J, Beetz N, Musialek R, Neely GG, Komnenovic V, Kolm U, Metzler B, Ricci R, Hara H, Meixner A, Nghiem M, Chen X, Dawood F, Wong KM, Sarao R, Cukerman E, Kimura A, Hein L, Thalhammer J, Liu PP, Penninger JM. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Cir Res 2007;101:e32-42. [original work]
    2. Shalev I, Liu H, Koscik C, Bartczak A, Javadi M, Wong KM, Maknojia A, He W, Liu MF, Diao J, Winter E, Manuel J, McCarthy D, Cattral M, Gommerman J, Clark DA, Phillips MJ, Gorczynski RR, Zhang L, Downey G, Grant D, Cybulsky MI, Levy G. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. J Immunol 2008;180:249-60. [original work]
    3. Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, Zhang J, Ma XZ, Yang XC, Gao JF, Liu H, Selzner N, Clark DA, Adeyi O, Phillips MJ, Gorczynski RR, Grant D, McGilvray I, Levy G. The novel CD4+CD25+ regulatory T cell effector molecule Fibrinogen-Like Protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology 2009;49:387-97. [original work]
    4. Foerester K, Helmy A, Zhu Y, Khattar R, Adeyi OA, Wong KM, Shalev I, Clark DA, Wong PY, Heathcote EJ, Phillips MJ, Grant DR, Renner EL, Levy GA, Selzner N. The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol 2010;53:608-15. [original work]
    5. Wong KM, Khanna M, Wu RC, Hedley DW. Gemcitabine-induced acute myositis in a patient with duodenal cancer. Clin Oncol (R Coll Radiol) 2011;23:492-3. [case report]
    6. *Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet 2011;12:407-30. [review]
    7. Wong KM, Chugh S, Lee DS. Fever and multiorgan infarcts in a 35-year-old man. CMAJ 2012;184:783-8. [case report]
    8. Wong KM, Atenafu EG, Kim D, Kuruvilla J, Lipton JH, Messner H, Gupta V. Incidence, risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1589-99. [original work]
    9. Golan E, Wong K, Al-Alahmadi H, Agid RF, Morris A, Sharkawy A, Zadeh G. Endoscopic sphenoid sinus drainage in Lemierre syndrome. J Clin Neurosci 2014;21:346-8. [case report]
    10. Wong KM, Qiu X, Cheng D, Azad AK, Habbous S, Palepu P, Mirshams M, Patel D, Chen Z, Roberts H, Knox J, Marquez S, Wong R, Darling G, Waldron J, Goldstein D, Leighl N, Shepherd FA, Tsao M, Der S, Reisman D, Liu G. Two BRM promoter insertion polymorphisms increase the risk of early stage upper aerodigestive tract cancers. Cancer Med 2014;3:426-33. [original work]
    11. Wong KM, Noonan S, O’Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive advanced non-small cell lung cancer. Drugs Today (Barc) 2015;51:161-70. [review]
    12. Noonan S, Wong KM, Jimeno A. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer. Drugs Today (Barc) 2015;51:357-66. [review]
    13. Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Am Soc Clin Oncol Educ Book 2015;35:3-8. [review]
    14. *Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol 2016;13:106-17. [review]
    15. Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB. A cost-effectiveness analysis of using the JBR.10-based 15-gene expression signature to guide adjuvant chemotherapy in early stage non-small cell lung cancer. Clin Lung Cancer 2017;18:e41-e47. [original work]
    16. Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore S, Smith PG, McDonald A, Berger A, Tentler JJ, Eckhardt SG. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Invest New Drugs 2017;35:11-25. [original work]
    17. Wong KM, Grady WM. Colorectal Cancer Heterogeneity: Evolving Classification Schemes for Prognostication and Prediction for Response to Therapy. Gastrointestinal Cancers Symposium Daily News, January 19, 2017. [editorial]
    18. Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP. ­­Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). Curr Oncol Rep 2017;19:47. [review]

 

  1. Book chapters
    1. Mohareb M, Sharma S, Wong KM (Chapter Editors). Cardiology and Cardiovascular Surgery. In Dugani S, Lam D (Editors-in-Chief), The Toronto Notes 2009: Comprehensive Medical Reference and Review for MCCQE I and USMLE II, 25th edition, Type and Graphics Inc., Toronto, Canada, 2009.
    2. Wong KM (Primary Chapter Author), Kohly R, Muni R, Lam WC. Chapter 16: Ophthalmology. In Chowdhury JH, Merani S (Editors-in-Chief), Essentials for the Canadian Medical Licensing Exam: Review and Prep for MCCQE Part 1, 1st edition, Lippincott Williams & Wilkins, Baltimore, USA, 2009.
    3. Capasso A, Wong KM, Eckhardt SG. Chapter 2: Biology of normal and tumour cells (self-sufficiency and insensitivity to anti-proliferative, apoptosis, limitless replicative potential). In Tortora G et al. (Editors), ESMO Handbook on Translational Research, ESMO Press, Switzerland, 2015.

 

  1. Other publications
    1. Wong KM. A balancing act – uncoupling of proliferation and apoptosis in tumourigenesis. UTMJ 2006;83:162-3. [review]
    2. Yu K, Wong KM. Dr. Albert J. Schumacher: raising awareness, showing direction, and creating results in the medical profession. UTMJ 2006;84:48-50. [interview]
    3. Wong KM. The CD28/CTLA-4/B7 pathway in immunological regulation: the basis of disease and the promise of therapy. UTMJ 2007;84:131-5. [review]
    4. Wong KM. Case report: thrombotic thrombocytopenic purpura. UTMJ 2009;86:47-52. [case report]

 

  1. Abstracts
    1. Wong KM, Atenafu EG, Kim D, Kuruvilla J, Lipton JH, Messner H, Gupta V. Incidence, risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, New York, NY, USA. November 3-4, 2011. (Oral and poster presentations, 3rd Place Abstract Award)
    2. Wong KM, Qiu X, Cheng D, Azad AK, Palepu PR, Mirshams M, Patel D, Chen Z, Roberts H, Knox JJ, Wong R, Darling GE, Waldron JN, Goldstein DP, Leighl NB, Shepherd FA, Tsao MS, Der S, Reisman D, Liu G. The association between two BRM promoter sequence variants and the risk of stage I and II upper aerodigestive tract cancers. 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. June 1-5, 2012. J Clin Oncol 2012;30 (suppl; abstr 10522). (Poster presentation with poster discussion, ASCO Merit Award)
    3. Wong KM, Victor C, Eng L, Verma S. The role of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: a meta-analysis study. 2013 Canadian Association of Medical Oncologists (CAMO) Annual Scientific Meeting, Toronto, ON, Canada. April 25, 2013. (Oral presentation, 2nd Place Abstract Award)
    4. Wong KM, Cuffe S , Coate L, Espin-Garcia O, Boyd K, Feld R, Leighl N, Shepherd FA, Xu W, Liu G. The impact of body mass index on survival in stage 3 and 4 lung cancer. 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. May 31-June 4, 2013. J Clin Oncol 2013;31 (suppl; abstr 1579). (Poster presentation, ASCO Merit Award)
    5. Wong KM, Cuffe S , Coate L, Espin-Garcia O, Boyd K, Feld R, Leighl N, Shepherd FA, Xu W, Liu G. The impact of body mass index on survival in stage 3 and 4 lung cancer. 15th World Conference on Lung Cancer, Sydney, Australia. October 27-30, 2013. (O24.05) (Oral presentation)
    6. Wong KM, Li S, Ding K, Bradbury P, Tsao MS, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB. A cost-effectiveness analysis of the 15-gene expression signature in guiding adjuvant chemotherapy in early stage non-small cell lung cancer based on the JBR.10 trial. 15th World Conference on Lung Cancer, Sydney, Australia. October 27-30, 2013. (MO08.08) (Mini-oral presentation)
    7. Wong KM, Liu G, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown MC, Wong A, Reisman D, Xu W, Knox J, Cleary SP, Hung R. BRM promoter insertion/deletion polymorphisms in hepatocellular carcinoma risk and survival. 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, USA. January 16-18, 2014. J Clin Oncol 2014;32 (suppl 3; abstr 225). (Poster presentation)
    8. Wong KM, Lee JJ, Wong A, Liu G, Sherman M, Cleary S, Knox J. Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians. 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, USA. January 16-18, 2014. J Clin Oncol 2014;32 (suppl 3; abstr 289). (Poster presentation)
    9. Wong KM, Chiu J, Shen X, Templeton R, Xu W, Chen E, Feld R, Sherman M, Knox J. Impact of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on outcomes in hepatocellular carcinoma (HCC) patients on sorafenib (Sor). ESMO 2014 Congress, Madrid, Spain. September 26-30, 2014. (abstr 5122) (Poster presentation)
    10. Wong KM, Tan AC, Pitts T, Devaraj K, Klauck P, Earp S, Frye S, Wang X, Kopetz S, Graham D, Eckhardt SG. MER as a novel therapeutic target in colorectal cancer. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain. November 18-21, 2014. (abstr 375) (Poster presentation)
    11. Wong KM, Gao D, McCoy H, Brock A, Powell RW, O’Bryant C, Camidge DR, Gore L, Jimeno A, Diamond JR, Messersmith WA, Eckhardt SG, Leong S. Predicting outcomes in patients with advanced malignancies treated on phase 1 clinical trials. 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. May 29-June 2, 2015. J Clin Oncol 2015;33 (suppl; abstr 2543). (Poster presentation)
    12. Wong KM, Rubinstein L, Rinker M, Smith GL, Sharon E, Eckhardt SG, Messersmith WA, Leong S, Harris PJ, Gao D. Prognostic factors for 90-day mortality in patients with solid malignancies treated on Phase 1 trials sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA. June 3-7, 2016. J Clin Oncol 2016;34 (suppl; abstr 2533). (Poster presentation)

 

  1. OTHER
  1. Invited meetings/conferences (competitive application)

2013              Amgen Canada Fellows Alliance ASCO Program Award (at ASCO Annual Meeting), Chicago, IL, June 3, 2013.

2013              Cancer Education Consortium Molecular and Translational Oncology Workshop, Sanibel Harbour Marriott, Fort Myers, FL, June 14-18, 2013.

2013              Cancer Education Consortium Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development, Lansdowne Conference Center, Leesburg, VA, October 11-14, 2013.

2013              Impact Grant Panel Meeting, Canadian Cancer Society Research Institute, Toronto, ON, Canada, November 18, 2013.

2014              AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO, July 26-August 1, 2014.

2016              ASCO/EORTC/NCI Markers in Cancer Diagnostic Development Tutorial, Bethesda, MD, May 2-3, 2016.

 

  1. Special electives and training

2015              CTEP Fellowship, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, November 2-28, 2015.

2016              Residents and Fellows as Educators Elective, University of Colorado Anschutz Medical Campus, Aurora, CO, May 2-20, 2016.

 

C.               Invited regional, national and international lectures

2017                            Hepatocellular carcinoma treatment options: current and future immunotherapy.” Practical Recommendations in Immuno & Molecular Oncology, 2nd Annual Meeting, Maui, HI, February 9-12, 2017.

2017              “Investigating the receptor tyrosine kinase MER as a novel therapeutic target in colorectal cancer.” The 5th International Symposium of Training Plan for Oncology Professionals, Osaka, Japan, March 11-12, 2017.

2017              “Gastroenteropancreatic neuroendocrine tumors.” The 2017 Seattle Neuroendocrine Cancer Patient Conference, Seattle, WA, May 6, 2017.

 

Page 1 of 10